United Therapeutics Stock (NASDAQ:UTHR)


ForecastRevenueOwnershipFinancialsChartTranscripts

Previous Close

$360.71

52W Range

$208.62 - $417.82

50D Avg

$363.50

200D Avg

$300.17

Market Cap

$16.27B

Avg Vol (3M)

$370.68K

Beta

0.56

Div Yield

-

UTHR Company Profile


United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Tyvaso, an inhaled formulation of prostacyclin analogue treprostinil to enhance the exercise ability in PAH patients and pulmonary hypertension associated with interstitial lung disease (PH-ILD); Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Unituxin, a monoclonal antibody for treating high-risk neuroblastoma; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. The company also engages in developing Tyvaso DPI, a dry powder inhalation form of Tyvaso; Remunity Pump, a small, lightweight, durable pump and separate controller; RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Tyvaso PERFECT and TETON studies, which are the studies of Tyvaso in patients with World Health Organization (WHO) Group 3 pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD). It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

1,168

IPO Date

Jun 17, 1999

Website

UTHR Performance


Revenue Breakdown


Revenue Breakdown by Product/Service

Product/ServiceDec 23Dec 22Dec 21
Adcirca$28.90M$55.90M-
Unituxin$198.90M$182.90M$202.30M
Product and Service, Other$11.80M$13.80M-
Tyvaso$1.23B$873.00M$607.50M
Remodulin$494.80M$500.20M$513.70M
Orenitram$359.40M$325.10M$306.10M

Fiscal year ends in Dec 23 | Currency in USD

UTHR Financial Summary


Dec 23Dec 22Dec 21
Revenue$2.33B$1.94B$1.69B
Operating Income$1.18B$979.70M$555.90M
Net Income$984.80M$727.30M$475.80M
EBITDA$1.39B$984.70M$614.80M
Basic EPS$21.04$15.98$10.60
Diluted EPS$19.81$15.00$10.06

Fiscal year ends in Dec 23 | Currency in USD

Latest Earnings Call Transcripts


Q3 24Oct 30, 24 | 3:09 PM
Q2 24Jul 31, 24 | 11:28 AM
Q1 24May 01, 24 | 12:00 AM

Peer Comparison


TickerCompany
NUVLNuvalent, Inc.
INCYIncyte Corporation
AKROAkero Therapeutics, Inc.
KNSAKiniksa Pharmaceuticals, Ltd.
APLSApellis Pharmaceuticals, Inc.
LRMRLarimar Therapeutics, Inc.
BPMCBlueprint Medicines Corporation
DAWNDay One Biopharmaceuticals, Inc.
VTYXVentyx Biosciences, Inc.
BGNEBeiGene, Ltd.
ALNYAlnylam Pharmaceuticals, Inc.
REPLReplimune Group, Inc.
LEGNLegend Biotech Corporation
ASNDAscendis Pharma A/S
MNKDMannKind Corporation
PCVXVaxcyte, Inc.
RAREUltragenyx Pharmaceutical Inc.